Characteristics of patients with available 5ʹRACE data (n = 75) in the PMBL LYSA cohort
| Characteristics . | 5′RACE set (n = 75) . |
|---|---|
| Age, median (Q1; Q3, min-max), y | 33 (26; 41.5, 18-64) |
| Female sex | 40 (53.33%) |
| ECOG 0-1 | 65 (86.67%) |
| Ann Arbor stage I-II | 43 (57.33%) |
| Elevated LDH | 61 (81.33%) |
| IPI 0 | 9 (12%) |
| IPI 1-2 | 48 (64%) |
| IPI 3-5 | 18 (24%) |
| Bulky mass ≥10 cm | 45 (60%) |
| Extranodal involvement | 43 (57.33%) |
| First-line treatment | |
| Anti CD20 + ACVBP | 54 (72%) |
| Anti CD20 + CHOP14 | 11 (14.67%) |
| Anti CD20 + CHOP21 | 10 (13.33%) |
| Baseline median MTV (Q1; Q3, min-max), cm3 | 260 (146; 407, 20-1147) |
| MTV ≥360 cm3 | 21 (35%) |
| GEP assay (RT-MLPA) | |
| CD20 expression, median (Q1; Q3, min-max) | 9.56 (4.64; 14.79, 0.75-42.08) |
| High CD20 gene expression (greater than median) | 37 (49.3%) |
| MAL expression, median (Q1; Q3, min-max) | 0.89 (0.35; 3.06, 0.02-21.05) |
| High MAL expression (greater than median) | 37 (49.3%) |
| CD3 expression, median (Q1; Q3, min-max) | 1.92 (1.31; 3.05, 0.22-8.01) |
| Low CD3 expression (less than or equal to median) | 38 (50.7%) |
| CD68 expression, median (Q1; Q3, min-max) | 7.38 (5.63; 8.74, 2.39-24.07) |
| Low CD68 expression (less than or equal to median) | 38 (50.7%) |
| AID expression, median (Q1; Q3, min-max) | 1.61 (0.65; 2.69, 0-18.53) |
| High AID expression (greater than median) | 37 (49.3%) |
| High PDL1/PDL2 expression (PDL1 > 0.402; PDL2 > 9.147) | 22 (29.33%) |
| 5′RACE assay | |
| Presence of a fusion transcript involving IgVH or IgVL | 6 (8%) |
| Characteristics . | 5′RACE set (n = 75) . |
|---|---|
| Age, median (Q1; Q3, min-max), y | 33 (26; 41.5, 18-64) |
| Female sex | 40 (53.33%) |
| ECOG 0-1 | 65 (86.67%) |
| Ann Arbor stage I-II | 43 (57.33%) |
| Elevated LDH | 61 (81.33%) |
| IPI 0 | 9 (12%) |
| IPI 1-2 | 48 (64%) |
| IPI 3-5 | 18 (24%) |
| Bulky mass ≥10 cm | 45 (60%) |
| Extranodal involvement | 43 (57.33%) |
| First-line treatment | |
| Anti CD20 + ACVBP | 54 (72%) |
| Anti CD20 + CHOP14 | 11 (14.67%) |
| Anti CD20 + CHOP21 | 10 (13.33%) |
| Baseline median MTV (Q1; Q3, min-max), cm3 | 260 (146; 407, 20-1147) |
| MTV ≥360 cm3 | 21 (35%) |
| GEP assay (RT-MLPA) | |
| CD20 expression, median (Q1; Q3, min-max) | 9.56 (4.64; 14.79, 0.75-42.08) |
| High CD20 gene expression (greater than median) | 37 (49.3%) |
| MAL expression, median (Q1; Q3, min-max) | 0.89 (0.35; 3.06, 0.02-21.05) |
| High MAL expression (greater than median) | 37 (49.3%) |
| CD3 expression, median (Q1; Q3, min-max) | 1.92 (1.31; 3.05, 0.22-8.01) |
| Low CD3 expression (less than or equal to median) | 38 (50.7%) |
| CD68 expression, median (Q1; Q3, min-max) | 7.38 (5.63; 8.74, 2.39-24.07) |
| Low CD68 expression (less than or equal to median) | 38 (50.7%) |
| AID expression, median (Q1; Q3, min-max) | 1.61 (0.65; 2.69, 0-18.53) |
| High AID expression (greater than median) | 37 (49.3%) |
| High PDL1/PDL2 expression (PDL1 > 0.402; PDL2 > 9.147) | 22 (29.33%) |
| 5′RACE assay | |
| Presence of a fusion transcript involving IgVH or IgVL | 6 (8%) |
ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; LDH, lactate dehydrogenase; min-max, minimum-maximum; Q, quartile; RT-MLPA, reverse transcription multiplex ligation-dependent probe amplification.